# Biomarin Pharmaceutical (BMRN.US)

Canonical: https://gigainvestors.com/s/BMRN

Analysis as of: 2026-10-16T07:27:01.142Z. Financial observations: FY1998–FY2026.

Listing currency: USD. Reporting currency: USD.

## Verdict

Not a wonderful business

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $56.05 per share; close as of 2026-10-15.

Estimated value: low $20.74 per share, central $27.85 per share, high $31.98 per share. Buy at or below the central value $27.85 per share. Valuation as of 2026-10-16T07:27:01.142Z; scenarios are not confidence intervals.

Expected annual return: 6.3% at the stated quote. About 6.3% a year at today's price (required return 10.0%). required return 10.0% a year (10% floor; US 10-year bond 5.1% + 4 points).

## Checklist

### understandable: fail

- 1 revenue decline in the last 10 years (informational)

- more than 2 net loss years

- operating margin variation exceeds 0.35

- Financial history: 10 years

- Years with declining revenue: 1

- Years with a net loss: 4

- Operating margin variation: 2.49×

Chart: Operating margin; fiscal year observations.

- FY2017: -0.01×

- FY2018: -0.08×

- FY2019: -0.06×

- FY2020: -0.02×

- FY2021: -0.04×

- FY2022: 0.08×

- FY2023: 0.08×

- FY2024: 0.17×

- FY2025: 0.17×

- LTM to Jun 2026: 0.08×

### moat: fail

- ROIC median below threshold

- ROIC worst years below threshold (more than 1 bad year allowed)

- ROIC, median of available years: -0.7%

- ROIC, second-lowest year: -3.9%

- Typical minus recent gross margin: 1.3 pp

- Typical gross margin (annual median): 78.4%

- Recent gross margin (lower of latest and 3-year median): 77.1%

- Years with nonpositive capital: 0

- Capital spending / revenue: 6.9%

- ROIC including acquisitions, ten-year median: 1.2%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2016: -25.8%

- FY2017: -0.5%

- FY2018: -3.9%

- FY2019: -2.6%

- FY2020: -0.9%

- FY2021: -1.6%

- FY2022: 3.6%

- FY2023: 3.5%

- FY2024: 7.7%

- FY2025: 7.8%

### economics: fail

- working capital as a share of revenue rose more than 10pp and ends positive

- Owner earnings / net income, 5-yr: 0.99×

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: $1.0B

- Net income, five-year total: $1.0B

- Return on incremental invested capital: 21.6%

- Working capital / revenue, annual change: 2.5 pp

- Working capital / revenue, change between three-year averages: 17.9 pp

- Working capital / revenue, final three-year average: 58.6%

Chart: Annual owner cash / profit; fiscal year observations.

- FY2021: 1.17×

- FY2022: 1.00×

- FY2023: 1.00×

- FY2024: 1.00×

- FY2025: 1.00×

### management: pass

- Historical market-dollar context (not the management verdict): 2016 to 2025 (9 years)

- potential debt-funded buybacks (informational)

- buybacks leaned toward cheaper years (informational)

- ROIC first 3 years vs last 3 years: -3.9% vs 7.7%

- Per-share earnings: -1.07 to 1.77 (three-year endpoint medians)

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 10-year annual growth: 2.1%

- Ordinary dilution, 5-year annual growth: 0.6%

- Market cap gain: -$2.9B

- Cumulative retained earnings: $1.7B

- Diluted shares, 10-year annual growth: 2.1%

- Diluted shares, 5-year annual growth: 0.6%

- $1 test, starting fiscal year: FY2016

- $1 test, ending fiscal year: FY2025

- Per-share value change: $2.84

- Per-share value, starting three-year median: -$1.07

- Per-share value, ending three-year median: $1.77

- Buybacks concentrated in cheaper years (correlation): 0.52

- Average buyback yield: 0.3%

- Buyback history: 9 years

- Debt-funded buybacks: Yes

- Acquisition spending: $0

- Cumulative net income, 10 years: $1.0B

- ROIC, first three-year median: -3.9%

- ROIC, last three-year median: 7.7%

Chart: Earnings per share; fiscal year observations.

- FY2016: -$3.79

- FY2017: -$0.67

- FY2018: -$0.44

- FY2019: -$0.13

- FY2020: $4.46

- FY2021: -$0.35

- FY2022: $0.75

- FY2023: $0.87

- FY2024: $2.17

- FY2025: $1.77

### accounting: pass

- stock compensation exceeds 15% of operating cash flow

- Sloan accruals: -6.3%

- Receivables to sales index (DSRI): 1.22×

- Restructuring years, last five: 0

- Stock compensation / operating cash flow: 21.9%

- Earnings backed by cash: Yes

- Operating cash / earnings: 2.37×

- Accounting red flags: 1

- Goodwill and intangibles / equity: 0.07×

Chart: Sloan accruals; fiscal year observations.

- FY2016: -10.0%

- FY2017: -2.3%

- FY2018: -2.2%

- FY2019: -1.5%

- FY2020: 13.1%

- FY2021: -6.1%

- FY2022: -0.5%

- FY2023: 0.1%

- FY2024: -2.1%

- FY2025: -6.3%

## Holders

- [David Hoeft](https://gigainvestors.com/DAC): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Robert Torray](https://gigainvestors.com/T): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Andreas Halvorsen](https://gigainvestors.com/vg): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 51% since Jan 2023 · "BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market" (finance.yahoo.com, Feb 2026) · sales +5.8%

Story as of 2026-10-16T09:58:24.961Z; price observation 2026-10-15.

Price needs cash profits to grow 16.5% a year for ten years

- 2025-08-05: BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 ([seekingalpha.com](https://seekingalpha.com/news/4478059-biomarin-raises-2025-full-year-guidance-with-3_125b-revenue-target-and-advances-bmn-333?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2025-11-27: BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength ([finance.yahoo.com](https://finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-evaluating-valuation-001514359.html))

- 2025-12-20: BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus ([finance.yahoo.com](https://finance.yahoo.com/news/biomarin-bmrn-jumps-17-7-131309707.html))

- 2026-02-24: BioMarin signals $3.325B–$3.425B 2026 revenue target as acquisitions and pipeline drive growth ([seekingalpha.com](https://seekingalpha.com/news/4555585-biomarin-signals-3_325b-3_425b-2026-revenue-target-as-acquisitions-and-pipeline-drive-growth?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2026-05-20: BioMarin gains on Voxzogo phase 3 results ([seekingalpha.com](https://seekingalpha.com/news/4595525-biomarin-gains-voxzogo-phase-3-results?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2026-08-07: BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/bmrn-stock-q2-earnings-beat-155000668.html))

### Sales · FY2025–2026

sales +5.8%; source https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm; observed 2026-02-26.

- FY2017: $1.3B 

- FY2018: $1.5B 

- FY2019: $1.7B 

- FY2020: $1.9B 

- FY2021: $1.8B 

- FY2022: $2.1B 

- FY2023: $2.4B 

- FY2024: $2.9B 

- FY2025: $3.2B 

- FY2026: $3.4B 

### Gross margin · FY2025

gross margin 77.1%; source https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm; observed 2026-02-26.

- FY2016: 81.2% 

- FY2017: 81.6% 

- FY2018: 78.9% 

- FY2019: 78.9% 

- FY2020: 71.8% 

- FY2021: 74.5% 

- FY2022: 76.0% 

- FY2023: 78.0% 

- FY2024: 79.7% 

- FY2025: 77.1% 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 3.2 billion.

- Source: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm (filed 2026-02-26); FY2025: revenue 3221253000; grossProfit 2484425000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); BMRN.US: BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

### Why customers stay

Margins ranged from 77.1% to 79.7% during 2023–25; it lost 0.7% on its capital.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2023: grossProfit / revenue = 78%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2024: grossProfit / revenue = 79.7%.

- Source: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm (filed 2026-02-26); FY2025: grossProfit / revenue = 77.1%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); 10-year return on capital observations [[2016,-0.25771862328944556],[2017,-0.004858739664770811],[2018,-0.03876979431945046],[2019,-0.026188690763953398],[2020,-0.008740565094638771],[2021,-0.01569294469469759],[2022,0.036197427696499265],[2023,0.0345730235437569],[2024,0.07670891988235307],[2025,0.07757385318783405]]; median -0.006799652379704792. ROIC follows the displayed moat series; financial companies use return on tangible equity.

### Where the cash goes

Spends 6.7% of cash earnings on expansion; earns 21.6% on new investment.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2020: growth capex 32347000; upkeep 105172000; owner earnings 854029000. Growth capex / owner earnings = 0.03787576300102222.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2022: growth capex 18990000; upkeep 101969000; owner earnings 141561000. Growth capex / owner earnings = 0.13414711679064148.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2023: growth capex 3225000; upkeep 104386000; owner earnings 167645000. Growth capex / owner earnings = 0.019237078350085.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); FY2024: growth capex 992000; upkeep 96426000; owner earnings 426859000. Growth capex / owner earnings = 0.00232395240582956.

- Source: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm (filed 2026-02-26); FY2025: growth capex 23481000; upkeep 79557000; owner earnings 348901000. Growth capex / owner earnings = 0.06729989309288308.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Incremental return on capital 0.21589944734739533, from the economics test's unchanged annual inputs.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Dividend observations: [[2016,0],[2017,0],[2018,0],[2019,11069000],[2020,71913000],[2021,3389000],[2022,15050000],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 0.3% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); BMRN.US SharesStats.PercentInsiders = 0.33999999999999997 percentage points; cache date 2026-10-16.

### What the price says

The price assumes cash profits grow 16.5% yearly over ten years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Ten-year compound average after fade. Initial solved rate 0.22602726121970274. Price 56.05; FX 1; discount 0.1; same standard ten-year fade to terminal 0.03. FY2015 owner earnings/share -1.630214153029744 → FY2025 1.767535994001844. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2016-10: $80.52 per share

- 2016-11: $85.63 per share

- 2016-12: $82.84 per share

- 2017-01: $87.63 per share

- 2017-02: $93.93 per share

- 2017-03: $87.78 per share

- 2017-04: $95.84 per share

- 2017-05: $87.64 per share

- 2017-06: $90.82 per share

- 2017-07: $87.73 per share

- 2017-08: $90.19 per share

- 2017-09: $93.07 per share

- 2017-10: $82.09 per share

- 2017-11: $85.80 per share

- 2017-12: $89.17 per share

- 2018-01: $90.23 per share

- 2018-02: $81.17 per share

- 2018-03: $81.07 per share

- 2018-04: $83.51 per share

- 2018-05: $90.34 per share

- 2018-06: $94.20 per share

- 2018-07: $100.56 per share

- 2018-08: $99.98 per share

- 2018-09: $96.97 per share

- 2018-10: $92.17 per share

- 2018-11: $96.03 per share

- 2018-12: $85.15 per share

- 2019-01: $98.17 per share

- 2019-02: $93.26 per share

- 2019-03: $88.83 per share

- 2019-04: $85.53 per share

- 2019-05: $82.24 per share

- 2019-06: $85.65 per share

- 2019-07: $79.32 per share

- 2019-08: $75.06 per share

- 2019-09: $67.40 per share

- 2019-10: $73.21 per share

- 2019-11: $80.71 per share

- 2019-12: $84.55 per share

- 2020-01: $83.50 per share

- 2020-02: $90.37 per share

- 2020-03: $84.50 per share

- 2020-04: $92.02 per share

- 2020-05: $106.55 per share

- 2020-06: $123.34 per share

- 2020-07: $119.81 per share

- 2020-08: $78.03 per share

- 2020-09: $76.08 per share

- 2020-10: $74.43 per share

- 2020-11: $78.70 per share

- 2020-12: $87.69 per share

- 2021-01: $82.78 per share

- 2021-02: $77.43 per share

- 2021-03: $75.51 per share

- 2021-04: $77.92 per share

- 2021-05: $77.30 per share

- 2021-06: $83.44 per share

- 2021-07: $76.73 per share

- 2021-08: $84.21 per share

- 2021-09: $77.29 per share

- 2021-10: $79.23 per share

- 2021-11: $86.29 per share

- 2021-12: $88.35 per share

- 2022-01: $88.63 per share

- 2022-02: $78.12 per share

- 2022-03: $77.10 per share

- 2022-04: $81.35 per share

- 2022-05: $75.13 per share

- 2022-06: $82.87 per share

- 2022-07: $86.05 per share

- 2022-08: $89.20 per share

- 2022-09: $84.77 per share

- 2022-10: $86.63 per share

- 2022-11: $100.98 per share

- 2022-12: $103.49 per share

- 2023-01: $115.35 per share

- 2023-02: $99.59 per share

- 2023-03: $97.24 per share

- 2023-04: $96.04 per share

- 2023-05: $86.94 per share

- 2023-06: $86.68 per share

- 2023-07: $87.93 per share

- 2023-08: $91.38 per share

- 2023-09: $88.48 per share

- 2023-10: $81.45 per share

- 2023-11: $91.08 per share

- 2023-12: $96.42 per share

- 2024-01: $88.08 per share

- 2024-02: $86.28 per share

- 2024-03: $87.34 per share

- 2024-04: $80.76 per share

- 2024-05: $75.07 per share

- 2024-06: $82.33 per share

- 2024-07: $84.33 per share

- 2024-08: $91.21 per share

- 2024-09: $70.29 per share

- 2024-10: $65.89 per share

- 2024-11: $66.03 per share

- 2024-12: $65.73 per share

- 2025-01: $63.36 per share

- 2025-02: $71.16 per share

- 2025-03: $70.69 per share

- 2025-04: $63.69 per share

- 2025-05: $58.07 per share

- 2025-06: $54.97 per share

- 2025-07: $57.85 per share

- 2025-08: $58.27 per share

- 2025-09: $54.16 per share

- 2025-10: $53.57 per share

- 2025-11: $55.93 per share

- 2025-12: $59.43 per share

- 2026-01: $56.54 per share

- 2026-02: $61.73 per share

- 2026-03: $56.49 per share

- 2026-04: $53.91 per share

- 2026-05: $57.29 per share

- 2026-06: $57.22 per share

- 2026-07: $60.02 per share

- 2026-08: $65.23 per share

- 2026-09: $60.00 per share

- 2026-10: $56.05 per share

## Annual estimated value (USD per share)

- FY2023: low $16.95 per share, central $21.91 per share, high $24.81 per share

- FY2024: low $19.16 per share, central $25.02 per share, high $28.43 per share

- FY2025: low $22.95 per share, central $29.54 per share, high $33.38 per share

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm); period 2025-12-31, filed 2026-02-26.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.